Plasma volume and electrolyte changes following intravenous infusion of hypertonic hydroxyethyl starch versus mannitol in healthy dogs.
In a prospective cross-over study, the duration and magnitude of effect on the electrolyte and plasma volume changes of intravenous (IV) hypertonic hydroxyethyl starch (hyperHES) (7.5%/6%) and mannitol (20%) were compared. Eight Beagle dogs received an IV infusion of 4mL/kg hyperHES (group H) and 4mL/kg mannitol 20% (group M) on separate occasions. Urine and blood samples were taken in the first (T(60)) and second (T(120)) hour after infusion. Significant increases in plasma volume at each time point in group H and M were noted when compared to baseline (start of infusion=T(0)) level. There was no significant difference between groups. Both fluids resulted in diuresis, although no significant difference between groups was noted. A significant increase in plasma sodium (Na) was demonstrated in group H between T(0) and T(60) with a significant increase in the Na and chloride (Cl) fractional excretion (FE) between T(0), T(60) and T(120). In group M no changes in plasma electrolyte concentrations were detected, although FE of Na, Cl and K was increased significantly between T(0) and T(60). In conclusion, hyperHES and mannitol appear to have a volume expanding effect lasting at least 120 min. The hypernatraemia induced by hyperHES was minimal compared to previous reports of hypertonic saline use, and no clinical side effects were noted. HyperHES showed comparable effects to mannitol in increasing plasma volume and diuresis and could be considered for these applications.
School of Veterinary Science, University of Liverpool, Leahurst, Neston, UK. Electronic address: beckyrobinson_85@yahoo.co.uk.
Rebecca
R
Robinson
University of Veterinary Medicine, Vienna, Austria.
Ilse
I
Schwendenwein
University of Veterinary Medicine, Vienna, Austria.
Sabine
S
Wacek
University of Veterinary Medicine, Vienna, Austria.
Barbara
B
Nell
Section of Anaesthesiology, Vet Suisse Faculty, University of Zürich, Switzerland.
Martina
M
Mosing
D000818:Animals; D018592:Cross-Over Studies; D004234:Diuretics, Osmotic / Q000494:pharmacology*; D004285:Dogs / Q000502:physiology*; D006895:Hydroxyethyl Starch Derivatives / Q000494:pharmacology*; D006982:Hypertonic Solutions; D007262:Infusions, Intravenous / Q000662:veterinary; D008353:Mannitol / Q000494:pharmacology*; D010952:Plasma Substitutes / Q000494:pharmacology*; D010953:Plasma Volume / Q000187:drug effects* / Q000662:veterinary; D011446:Prospective Studies; D013997:Time Factors; D014882:Water-Electrolyte Balance / Q000187:drug effects*
D004234:Diuretics, Osmotic; D006895:Hydroxyethyl Starch Derivatives; D006982:Hypertonic Solutions; D010952:Plasma Substitutes; D008353:Mannitol